drugset / Trial / NCT06161272
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, multicenter, two-arm, noncomparative, phase II study of fluzoparib with or without apatinib for maintenance therapy in PARPi-pretreated platinum-sensitive recurrent ovarian cancer. The primary objective is to evaluate median progression free survival of fluzoparib with or without apatinib.
Timeline
- Start
- 2023-12-10
- Primary completion
- 2025-03-10
- Completion
- 2026-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 100 mg | Oral |
| Subject | Fluzoparib | Small molecule | 150 mg | Oral |
| Subject | Rivoceranib | Small molecule | 375 mg | Oral |